17 June 2022

Graft Polymer (UK) Plc

("Graft Polymer", the "Company", and together with its subsidiaries, the "Group")

GraftBio IP - MGC Pharma Update

-      Graftbio's Platform used in MGC Pharmaceuticals Successful

-      Glioblastoma Pre-clinical Trial Results

Graft Polymer (UK) Plc (LSE: GPL), a business focused on the development and commercial production of polymer modification, biological supplements, and nano-drug delivery systems, is pleased to note the announcement issued by MGC Pharmaceuticals Ltd (LSE:MXC, ASX:MXC, "MGC Pharma") on 16 June 2022, regarding MGC Pharma's use of a base formulation nano delivery system, based on Graft Polymer's GraftBio IP, in relation to a pre-clinical research study in the use of cannabinoids to treat Glioblastoma multiforme cells, a fast-growing and aggressive form of brain cancer.

MGC Pharma, which uses Graft Polymer's drug delivery platforms in relation to MGC Pharma's CimetrA™ and CannEpil-IL™ products, confirmed that it has undertaken studies relating to the application of a base formulation nano delivery system, founded on the Company's GraftBio IP, to improve the bioavailability of the active compounds using a non-invasive drug administration process.  The study examined the toxicity of the base emulation to confirm its safety profile for potential use in future clinical research.

Victor Bolduev, CEO, commented:

"This important work being conducted by MGC Pharma, which is supported by Graft Polymer's GraftBio IP, is a real-world example of the enormous value of the research that we are undertaking.  Treating fatal cancerous brain tumours through the application of naturally derived cannabinoid products would be the definition of life-changing for so many people, and I am proud that Graft Polymer is such a critical partner in this effort." 

For more information, please visit https://www.graftpolymer.com or contact:

About Graft Polymer

Graft Polymer is a UK incorporated holding company with an innovative research and manufacturing facility, based in Slovenia. The core business of the Group comprises polymer modification and drug delivery systems developments. Established in 2017, the Group has already introduced more than 50 products to the market.

The Group has developed a proprietary set of polymer modification technologies, which can improve existing products and processing methodologies by enhancing performance, simplifying manufacturing, reducing material consumption, widening the choice of feedstocks, and reducing costs.

In particular, the Group's techniques allow the combination of otherwise incompatible polymers, facilitating the creation of polymer composites engineered at a molecular level, that combine the attractive properties of different input materials. This enables customers to receive a synergism of properties in polymer composites.

The solutions and products offered by the Group are designed to improve performance, reduce raw materials consumption, and enhance the physical characteristic values of finished products or improve or modify their chemical interaction. In the past several years, there has been increased emphasis by the industry as a whole on applications of grafted polymers, which are produced by monomers being covalently bonded and polymerised as side chains onto the main polymer chain (the backbone).

In 2020, the Group launched a new division named GraftBio to develop IP for Bio/Pharma applications. This includes a drug delivery system to support and provide solutions to the market, which had been heavily impacted by the COVID-19 pandemic. The GraftBio division has been granted HACCP certification for its production facility. The Group has developed a set of drug delivery platforms that enable it to licence its DDS platform (IP) to MGC Pharmaceuticals Limited ("MGC"; LSE: MXC) in relation to MGC's CimetrA™ and CannEpil-IL™ products. The Group expects to receive royalty payments resulting from the sale by MGC of CimetrA™ and CannEpil-IL™ products.